NEW YORK--(BUSINESS WIRE)--Remedy Pharmaceuticals, a company focused on the development and commercialization of CIRARA™, a breakthrough drug for treating acute central nervous system conditions, today announced the appointment of a new board member and two board advisors.
Joining as an independent board director is Kurt Landgraf, former head of DuPont Pharmaceuticals, part of DuPont (NYSE: DD) and past President and CEO of DuPont Merck Pharmaceuticals, which was acquired by Merck (NYSE: MRK) in 1998. Landgraf also held the positions at DuPont of Chief Financial Officer, Executive Vice President, Chief Operating Officer and Chairman of DuPont Europe.
Help employers find you! Check out all the jobs and post your resume.
Joining as an independent board director is Kurt Landgraf, former head of DuPont Pharmaceuticals, part of DuPont (NYSE: DD) and past President and CEO of DuPont Merck Pharmaceuticals, which was acquired by Merck (NYSE: MRK) in 1998. Landgraf also held the positions at DuPont of Chief Financial Officer, Executive Vice President, Chief Operating Officer and Chairman of DuPont Europe.
Help employers find you! Check out all the jobs and post your resume.
